2 days ago
8
MarketBeat
Thu, May 14, 2026 astatine 12:09 PM CDT 7 min read
Key Points
-
Interested successful Karyopharm Therapeutics Inc.? Here are 5 stocks we similar better.
-
Key objective catalysts are ahead for Karyopharm, including FDA engagement and work plans for its Phase 3 SENTRY myelofibrosis trial, positive an expected mid-2026 readout from the endometrial crab survey XPORT-EC-042.
-
The SENTRY trial showed a statistically important spleen measurement effect payment for selinexor positive ruxolitinib, on with an encouraging wide endurance awesome and nary caller information concerns, though the grounds endpoint was not statistically significant.
-
First-quarter gross roseate to $35.1 million, and Karyopharm reaffirmed full-year 2026 guidance; however, absorption said underlying XPOVIO request was weaker twelvemonth implicit twelvemonth owed to accrued competition.
Karyopharm Therapeutics (NASDAQ:KPTI) said it entered 2026 with respective near-term objective and regulatory catalysts, led by caller Phase 3 information successful myelofibrosis and an expected midyear readout successful endometrial cancer, portion reporting higher first-quarter gross and reaffirming full-year guidance.
On the company’s first-quarter net call, President and CEO Richard Paulson said Karyopharm has focused its enactment connected advancing late-stage objective programs, maintaining its commercialized basal successful aggregate myeloma and managing expenses arsenic it approaches “significant value-creating milestones.”
→ Rocket Lab Just Hit a New All-Time High—Time to Buy oregon Let It Breathe?
Paulson said the institution is present focused connected regulatory and technological engagement for its Phase 3 SENTRY proceedings successful myelofibrosis, preparing for top-line results from XPORT-EC-042 successful endometrial crab and maintaining fiscal discipline. He said Karyopharm’s existent operating program is expected to money operations into precocious successful the 3rd 4th of 2026.
SENTRY Data Show Spleen Volume Benefit, Survival Signal
Chief Medical Officer and Head of Research Reshma Rangwala said Karyopharm remains encouraged by top-line results from SENTRY, which evaluated selinexor successful operation with ruxolitinib successful myelofibrosis. The institution said the operation produced accelerated and sustained spleen measurement reductions, with the co-primary endpoint of SVR35 astatine week 24 reached by 50% of patients connected the operation versus 28% connected ruxolitinib alone. Rangwala said that effect was statistically significant, with a P worth of little than 0.0001.
→ MP Materials Is Quietly Building a Rare Earth Powerhouse
The trial’s 2nd co-primary endpoint, grounds betterment astatine week 24, was not statistically important by implicit full grounds people difference, though Rangwala said patients successful some arms had “important and akin betterment from baseline.”
English (CA) · 
English (US) · 
Spanish (MX) ·